The different isoforms of glutaminase can meet the metabolic needs of various types of tumors: the reduced expression or enzymatic activity of GLS produces antagonistic effects on lymphoma, glioma, breast, pancreas, non-small cell lung cancers and kidney cancers [13,14]. This evidence concerns the gene GLS and kidney cancer.